- Green Growth
- Your Consultant
|Ivermectin has been shown to be effective in vitro against a broad range of viruses|
Monash Biomedicine Discovery Institute’s Dr Kylie Wagstaff, who led the study, said the scientists showed that the drug, Ivermectin, stopped the SARS-CoV-2 virus growing in cell culture within 48 hours.
“We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours there was a really significant reduction in it,” Wagstaff said.
Ivermectin is an FDA-approved anti-parasitic drug that has also been shown to be effective in vitro against a broad range of viruses including HIV, Dengue, Influenza, and Zika virus.
|Dr Kylie Wagstaff|
Dr Wagstaff cautioned that the tests conducted in the study were in vitro and that trials needed to be carried out in people.
“Ivermectin is very widely used and seen as a safe drug. We need to figure out now whether the dosage you can use it at in humans will be effective – that’s the next step,” Wagstaff said.
"The use of Ivermectin to combat COVID-19 would depend on the results of further pre-clinical testing and ultimately clinical trials, with funding urgently required to keep progressing the work."
times when we’re having a global pandemic and there isn’t an approved treatment, if we had a compound that was already available around the world, that might help people sooner. Realistically, it’s going to be a while before a vaccine is broadly available."
“Although the mechanism by which Ivermectin works on the virus is not known, it is likely, based on its action in other viruses, that it works to stop the virus ‘dampening down’ the host cells’ ability to clear it,” she said.
Royal Melbourne Hospital’s Dr Leon Caly, a senior medical scientist at Victorian Infectious Diseases Reference Laboratory (VIDRL) at Doherty Institute where the experiments with live coronavirus were conducted, is the study’s first author.
“As the virologist who was part of the team who were first to isolate and share SARS-COV2 outside of China in January 2020, I am excited about the prospect of Ivermectin being used as a potential drug against COVID-19,” Caly said.
Dr Wagstaff made a previous breakthrough finding on Ivermectin in 2012 when she identified the drug and its antiviral activity with Monash Biomedicine Discovery Institute’s professor David Jans, also an author on this paper.
Professor Jans and his team have been researching Ivermectin for more than 10 years with different viruses. Wagstaff and Jans started investigating whether it worked on the SARS-CoV-2 virus as soon as the pandemic was known to have started.
The use of Ivermectin to combat COVID-19 would depend on the results of further pre-clinical testing and ultimately clinical trials, with funding urgently required to keep progressing the work, Wagstaff said.